Quiet on the insider front: nobody at Prime Medicine, Inc. bought or sold PRME shares with their own money this past year.
187 investment managers listed PRME in their latest 13F filings (Q2 2026); funds were split between buying and selling. Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 5, 2025 | Alphabet Inc. | 10% Owner | Buy | 1,500,000 | $3.30 | $5.0M | SEC |
| Aug 1, 2025 | NELSEN ROBERT | Director | Buy | 3,030,300 | $3.30 | $10.0M | SEC |
| Aug 1, 2025 | ARCH Venture Fund XII, L.P. | 10% Owner | Buy | 3,030,300 | $3.30 | $10.0M | SEC |
| Aug 1, 2025 | GILLIS STEVEN | 10% Owner | Buy | 3,030,300 | $3.30 | $10.0M | SEC |
| Jul 1, 2025 | Liu David R. | 10% Owner | Buy | 21,000 | $2.52 | $53K | SEC |
| Jun 23, 2025 | Liu David R. | 10% Owner | Buy | 21,000 | $2.16 | $45K | SEC |
| Jun 16, 2025 | Liu David R. | 10% Owner | Buy | 21,000 | $1.49 | $31K | SEC |
| Jun 12, 2025 | Liu David R. | 10% Owner | Buy | 21,000 | $1.60 | $34K | SEC |
| May 22, 2025 | Brudnick Richard | Executive Officer | Buy | 20,000 | $1.19 | $24K | SEC |
| May 22, 2025 | LEE ANN L. | Executive Officer | Buy | 100,000 | $1.13 | $113K | SEC |
| May 22, 2025 | Reine Allan | CEO | Buy | 125,000 | $1.18 | $148K | SEC |
| Feb 20, 2024 | NELSEN ROBERT | Director | Buy | 3,200,000 | $6.25 | $20.0M | SEC |
| Feb 20, 2024 | ARCH Venture Partners XII, LLC | 10% Owner | Buy | 3,200,000 | $6.25 | $20.0M | SEC |
| Feb 20, 2024 | ARCH Venture Partners X, L.P. | 10% Owner | Buy | 3,200,000 | $6.25 | $20.0M | SEC |
| Jun 22, 2023 | GV 2021 GP, L.P. | 10% Owner | Sell | 19,003 | $14.97 | $284K | SEC |
There were no open-market insider trades in PRME in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
187 investment managers reported holding PRME in SEC Form 13F filings for Q2 2026.
No congressional trades in PRME were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).